Department of Transplant and Infection Immunology, Institute of Virology, Saarland University, D-66421 Homburg, Germany.
J Clin Virol. 2010 Sep;49(1):53-7. doi: 10.1016/j.jcv.2010.06.020. Epub 2010 Jul 24.
Donor-derived transmission of hepatitis B virus (HBV) may cause serious complications after transplantation. To date, transplantation from HBV-infected donors to HBV-infected recipients seems feasible, although this is recommended with prophylaxis with specific drugs and antibodies only, whereas pre-emptive strategies are rarely used.
Here, we assessed the success of transplantation of kidneys from a chronically HBV-infected deceased donor (HBs-antigen positive, anti-HBc positive, HBV-DNA positive) to two recipients with cleared HBV-infection (HBs-antigen negative, anti-HBc positive, anti-HBs >100 IU/l) where risk-assessment was performed using a pre-emptive approach in the absence of prophylaxis.
Pre-emptive monitoring included assessment for evidence of infection by analysis of liver enzymes, viral load, and humoral and cellular immunity against HBV and CMV.
In line with undetectable HBV-load, HBc-specific T-cell frequencies remained stable (mean 0.46+/-0.10% and 0.06+/-0.03%), whereas CMV-specific T-cell frequencies in one patient showed dynamic changes that coincided with CMV-viremia. Likewise, HBV-specific antibody titres were stable. Liver enzymes demonstrated absence of liver-cell injury and renal function was good (creatinine 1.8 and 0.8 mg/dl at last follow-up after 39 and 38 months, respectively).
When combined with careful HBV-monitoring, kidneys from HBV-infected donors may be transplanted into HBV-immune recipients without the need for specific prophylaxis.
供体来源的乙型肝炎病毒(HBV)传播可能导致移植后发生严重并发症。迄今为止,从 HBV 感染供体向 HBV 感染受者移植似乎是可行的,尽管这仅推荐使用特定药物和抗体进行预防,而很少使用先发制人的策略。
在这里,我们评估了从慢性 HBV 感染的已故供体(HBs 抗原阳性,抗 HBc 阳性,HBV-DNA 阳性)向两名 HBV 感染已清除的受者(HBs 抗原阴性,抗 HBc 阳性,抗 HBs >100 IU/l)移植肾脏的成功情况,在没有预防的情况下,使用先发制人的方法进行风险评估。
先发制人的监测包括通过分析肝酶、病毒载量以及针对 HBV 和 CMV 的体液和细胞免疫来评估感染证据。
与不可检测的 HBV 载量一致,HBc 特异性 T 细胞频率保持稳定(平均值分别为 0.46+/-0.10%和 0.06+/-0.03%),而一名患者的 CMV 特异性 T 细胞频率显示出与 CMV 病毒血症相一致的动态变化。同样,HBV 特异性抗体滴度保持稳定。肝酶未显示肝细胞损伤,肾功能良好(最后一次随访时肌酐分别为 1.8 和 0.8 mg/dl,分别为 39 个月和 38 个月后)。
当与仔细的 HBV 监测相结合时,来自 HBV 感染供体的肾脏可移植到 HBV 免疫受者而无需特定预防。